Top Markets
#1 Islamic Coin Islamic Coin +151.30%
#2 Akedo Akedo +77.68%
#3 Glidr Glidr +51.75%
#4 DOVU DOVU +48.65%
#5 Cross Cross +44.14%
#6 Black Phoenix Black Phoenix +33.98%
#7 Velvet Velvet +25.65%
#8 Cap Cap +25.20%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.99%
#10 Palladium Network Palladium Network +12.46%
Coin of the day
Islamic Coin Islamic Coin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Clasificación en acciones #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Precio por acción
$0.38
Última sincronización: 2023-09-01
Capitalización bursátil
$677.16K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Aceragen, Inc. (ACGN)

Categoría

Healthcare
Ratio P/B de Aceragen, Inc. (ACGN)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Aceragen, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Aceragen, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE